Service de Neurologie, Hôpitaux Universitaires de Strasbourg, BP 426, F-67091 Strasbourg cedex, France.
- Page(s) : 159-66
- Année de parution : 2000
During the last few years many new antiepileptic drugs (AED) have been
marketed to treat epilepsy refractory to classic AED. Nevertheless, clinical
development is principally designed for licensing and not for clinical
practice use. So a majority of trials are of little value in terms of
treatment choice in a given patient . Lamotrigine (LTG) is licensed
in about 80 countries as add-on therapy in severe refractory epilepsy.